Alexander Coltoff

453 total citations
25 papers, 167 citations indexed

About

Alexander Coltoff is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Alexander Coltoff has authored 25 papers receiving a total of 167 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 10 papers in Genetics and 6 papers in Molecular Biology. Recurrent topics in Alexander Coltoff's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers), Acute Myeloid Leukemia Research (7 papers) and Multiple Myeloma Research and Treatments (5 papers). Alexander Coltoff is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers), Acute Myeloid Leukemia Research (7 papers) and Multiple Myeloma Research and Treatments (5 papers). Alexander Coltoff collaborates with scholars based in United States and Germany. Alexander Coltoff's co-authors include John Mascarenhas, Amir Steinberg, Guido Lancman, Sara Kim, Douglas Tremblay, Ralf Wagner, Benedikt Asbach, Stacy W. Blain, Angela L. Tyner and Erin Moshier and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Molecular and Cellular Biology.

In The Last Decade

Alexander Coltoff

23 papers receiving 166 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alexander Coltoff United States 8 84 66 58 44 27 25 167
Christos Demosthenous Greece 8 77 0.9× 64 1.0× 61 1.1× 71 1.6× 12 0.4× 19 202
Esperanza Lavilla Spain 8 82 1.0× 36 0.5× 100 1.7× 65 1.5× 13 0.5× 12 200
Ole Maywald Germany 7 142 1.7× 89 1.3× 20 0.3× 32 0.7× 38 1.4× 11 209
Daniela Žáčková Czechia 8 140 1.7× 109 1.7× 40 0.7× 25 0.6× 45 1.7× 34 175
Weerasak Nawarawong Thailand 8 119 1.4× 61 0.9× 55 0.9× 36 0.8× 5 0.2× 25 167
Ferran Vall‐Llovera Spain 6 64 0.8× 35 0.5× 47 0.8× 42 1.0× 6 0.2× 12 132
Christos Poziopoulos Greece 10 186 2.2× 81 1.2× 95 1.6× 118 2.7× 22 0.8× 19 259
Eun‐Jung Jang South Korea 10 130 1.5× 109 1.7× 18 0.3× 16 0.4× 66 2.4× 26 202
Feras Alfraih Saudi Arabia 8 63 0.8× 40 0.6× 24 0.4× 26 0.6× 8 0.3× 25 141
Uroš Markovic Italy 8 95 1.1× 33 0.5× 41 0.7× 60 1.4× 7 0.3× 36 188

Countries citing papers authored by Alexander Coltoff

Since Specialization
Citations

This map shows the geographic impact of Alexander Coltoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander Coltoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander Coltoff more than expected).

Fields of papers citing papers by Alexander Coltoff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexander Coltoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander Coltoff. The network helps show where Alexander Coltoff may publish in the future.

Co-authorship network of co-authors of Alexander Coltoff

This figure shows the co-authorship network connecting the top 25 collaborators of Alexander Coltoff. A scholar is included among the top collaborators of Alexander Coltoff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexander Coltoff. Alexander Coltoff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Coltoff, Alexander & John Mascarenhas. (2025). Fedratinib in 2025 and beyond: indications and future applications. Blood Advances. 9(8). 1907–1915. 2 indexed citations
2.
3.
Coltoff, Alexander & Andrew Kuykendall. (2024). Emerging drug profile: JAK inhibitors. Leukemia & lymphoma. 65(9). 1258–1269. 1 indexed citations
4.
Green, Kimberly, et al.. (2023). AML-399 Real-World Outcomes of Decitabine + Venetoclax With IDH Inhibition for AML. Clinical Lymphoma Myeloma & Leukemia. 23. S297–S297. 1 indexed citations
5.
Coltoff, Alexander, Andrew S. Bomback, Shayan Shirazian, Suzanne Lentzsch, & Divaya Bhutani. (2021). Treatment of Monoclonal Gammopathy-associated C3 Glomerulopathy With Daratumumab-based Therapy. Clinical Lymphoma Myeloma & Leukemia. 21(8). e674–e677. 5 indexed citations
6.
Coltoff, Alexander, et al.. (2021). Evaluating Race and Time to Transplantation in Multiple Myeloma: The Mount Sinai Hospital Experience. Clinical Lymphoma Myeloma & Leukemia. 21(7). 439–443. 2 indexed citations
7.
Moshier, Erin, Samantha E. Jacobs, Douglas Tremblay, et al.. (2020). Practicing Antimicrobial Stewardship: De-Escalating Antibiotics in Patients With Acute Myeloid Leukemia and Neutropenic Fever. Open Forum Infectious Diseases. 7(5). ofaa138–ofaa138. 7 indexed citations
8.
Coltoff, Alexander, Ruben A. Mesa, Jason Gotlib, et al.. (2020). Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera. Clinical Lymphoma Myeloma & Leukemia. 20(10). 697–703.e1. 11 indexed citations
9.
Coltoff, Alexander & John Mascarenhas. (2019). Relevant updates in systemic mastocytosis. Leukemia Research. 81. 10–18. 7 indexed citations
10.
Kamath, Geetanjali R., Douglas Tremblay, Alexander Coltoff, et al.. (2019). Comparing the epidemiology, clinical characteristics and prognostic factors of acute myeloid leukemia with and without acute promyelocytic leukemia. Carcinogenesis. 40(5). 651–660. 12 indexed citations
11.
Tremblay, Douglas, Eric Wilck, Amanda Leiter, et al.. (2019). Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms. Scientific Reports. 9(1). 16609–16609. 18 indexed citations
12.
Lancman, Guido, Alexander Coltoff, & Amir Steinberg. (2018). Romiplostim for thrombocytopenia following allogeneic stem cell transplantation. Hematology/Oncology and Stem Cell Therapy. 13(3). 171–174. 4 indexed citations
13.
Coltoff, Alexander, et al.. (2018). A single-institution experience of performing bloodless transplant in Jehovah’s Witness patients. Hematology/Oncology and Stem Cell Therapy. 12(1). 44–49. 7 indexed citations
14.
Coltoff, Alexander, Guido Lancman, Sara Kim, & Amir Steinberg. (2018). Vedolizumab for treatment of steroid-refractory lower gastrointestinal acute graft-versus-host disease. Bone Marrow Transplantation. 53(7). 900–904. 19 indexed citations
15.
Coltoff, Alexander, Jane Houldsworth, Alla Keyzner, Anne S. Renteria, & John Mascarenhas. (2018). Role of minimal residual disease in the management of acute myeloid leukemia—a case-based discussion. Annals of Hematology. 97(7). 1155–1167. 8 indexed citations
16.
Coltoff, Alexander, Elizabeth Lindenberger, Amy S. Kelley, et al.. (2018). Efficacy of a Novel Communication Skills Intervention for Practicing Oncologists (S735). Journal of Pain and Symptom Management. 55(2). 675–676. 1 indexed citations
17.
18.
Coltoff, Alexander, Guido Lancman, & Amir Steinberg. (2018). Romiplostim for Thrombocytopenia Following Allogeneic Stem Cell Transplantation: A Case Series. Clinical Lymphoma Myeloma & Leukemia. 18. S306–S306.
19.
Coltoff, Alexander, Douglas Tremblay, Marina Kremyanskaya, Ronald Hoffman, & John Mascarenhas. (2017). Real-World Outcomes of Ruxolitinib for Polycythemia Vera. Blood. 130. 2926–2926. 1 indexed citations
20.
Asbach, Benedikt, et al.. (2015). Brk/Protein Tyrosine Kinase 6 Phosphorylates p27 KIP1 , Regulating the Activity of Cyclin D–Cyclin-Dependent Kinase 4. Molecular and Cellular Biology. 35(9). 1506–1522. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christos Demosthenous Breakdown of academic impact, for papers by Esperanza Lavilla Breakdown of academic impact, for papers by Ole Maywald Breakdown of academic impact, for papers by Daniela Žáčková Breakdown of academic impact, for papers by Weerasak Nawarawong Breakdown of academic impact, for papers by Ferran Vall‐Llovera Breakdown of academic impact, for papers by Christos Poziopoulos Breakdown of academic impact, for papers by Eun‐Jung Jang Breakdown of academic impact, for papers by Feras Alfraih Breakdown of academic impact, for papers by Uroš Markovic
Rankless by CCL
2026